CN1349422A - Contraceptive compositions containing cyclic carbramates and amide derivatives - Google Patents
Contraceptive compositions containing cyclic carbramates and amide derivatives Download PDFInfo
- Publication number
- CN1349422A CN1349422A CN 00807137 CN00807137A CN1349422A CN 1349422 A CN1349422 A CN 1349422A CN 00807137 CN00807137 CN 00807137 CN 00807137 A CN00807137 A CN 00807137A CN 1349422 A CN1349422 A CN 1349422A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- replacement
- daily dose
- alkoxyl
- progestogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
This invention relates to cyclic combination therapies and regimens utilizin g, in combination with progestins, estrogens, or both, substituted indoline derivative compounds which are antagonists of the progesterone receptor having general structure (I) wherein A and B are independent substituents selected from S, CH or N; provided that when A is S, B is CH or N; and when B is S, A is CH or N; and A and B cannot both be CH; and when A and B both equal N, on e N may be optionally substituted with a C1 to C6 alkyl group; R1 and R2 are independent substituents selected from the group of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C2 to C6 alkenyl, substituted C2 to C6 alkenyl, C2 to C6 alkynyl, substituted C2 to C6 alkynyl, C3 to C8 cycloalkyl, substitute d C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, CORA, or NRBCORA; or R1 and R2 are fused to form optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring, the heterocyclic ring containing one to three heteroatoms selected from the group of O, S and N; or pharmaceutically useful salts thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.
Description
Invention field
The present invention relates to administration therapeutic method with the agonist compounds of the progesterone receptor of progestogen, estrogen or the two coupling.
Background of invention
Intracellular receptor (IR) forms the relevant Gene regulation agent of a class formation, is called " ligand dependent transcription factor " (R.M.Evans, Science, 240,889,1988).Steroid receptor family is a subclass of IR family, comprises progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR) (GR) and mineralcorticoid receptor (MR).
For PR natural hormone or part is the steroid Progesterone, but has also synthesized chemical compound such as medroxyprogesterone acetate or levonorgestrel as part.In case have part in the pericellular liquid, part is just by the passive film that diffuses through, and combines with IR and to produce the receptor/ligand complex.This complex transporte to cells nuclear combines with the specific gene that exists in the cell DNA then.In case be incorporated into DNA sequence, this complex is with regard to the proteinic generation of regulating mRNA and this gene code.
The chemical compound that is incorporated into IR and the effect of simulation natural hormone is called agonist, and the chemical compound of inhibitory hormone effect is called antagonist.Known PR antagonist (natural and synthetic) plays an important role in women's health.The PR antagonist is used for the birth control preparation, when especially having the ER agonist.The ER agonist is used for the treatment of the disease in menopause, but discovery is relevant with the proliferative effect of uterus (women who does not hysterectomize), will cause increasing the danger of ovarian cancer.Can reduce/remove this danger with the coupling of PR agonist.The PR antagonist also can be used for contraception.They can give (people such as Ulmann separately in this case, Ann.N.Y.Acad.Sci., 261,248,1995), also can with PR agonist coupling (people such as Kekkonen, Fertility and Sterility, 60,610,1993) or with part ER antagonist (as Tamoxifen Citrate) coupling (WO 96/19997 A1 on July 4th, 1996).
The PR antagonist also can be used for the treatment of hormonal dependent breast carcinoma (283, publisher: Birkhaeuser, Boston, Mass writes Vedeckis for people such as Horwitz, Horm.Cancer) and uterus carcinoma and ovarian cancer.The PR antagonist also can be used for treating non-pernicious chronic disease such as fibroma (people such as Murphy, J.Clin.Endo.Metab., 76,513,1993) and endometriosis (people such as Kettel, Fertility and Sterility, 56,402,1991).
The PR antagonist also can be used for hormone replacement therapy, treats postclimacteric patient (US5719136) with part ER antagonist (as Tamoxifen Citrate) coupling.PR antagonist such as mifepristone have demonstrated the effect that rodent ulcer is had skeleton protection, therefore can be used for treating relevant osteoporosis in menopause people such as (, Bone, 17,21,1995) Barengolts.Be presented in the hormonal dependent carcinoma of prostate model, PR antagonist (as mifepristone and onapristone) is effectively, shows that they can be used for treating this class disease of male people such as (, Ann.N.Y.Acad.Sci., 761,224,1995) Michna.
The chemical compound that people such as Jones (U.S. Patent No. 5,688,810) describe is a PR antagonist dihydroquinoline 1.
People such as Jones (U.S. Patent No. 5,693,646) have described the enol ether 2 as the PR part.
People such as Jones (U.S. Patent No. 5,696,127) have described the chemical compound 3 as the PR part.
People such as Zhi (J.Med.Chem., 41,291,1998). the lactone 4,5 and 6 as the PR antagonist has been described.
People such as Zhi have described the ether 7 (J.Med.Chem., 41,291,1998) as the PR antagonist.
People such as Combs disclose the amide 8 (J.Med.Chem., 38,4880,1995) as the PR part.
People such as Perlman have described the novel vitamin D analogues 9 (Tet.Letters, 35,2295,1994) as the PR part.
People such as Hamann have described PR antagonist 10 (Ann.N.Y.Acad.Sci., 761,383,1995).
People such as Chen have described PR antagonist 11 (people POI-37 such as Chen, 16
ThIht.Cong.Het.Chem., Montana, 1997).
People such as Kurihari have described PR ligand 12 (J.Antibiotics, 50,360,1997).
U.S. Patent No. 5,521,166 (Grubb) point out that cycle stage property (cyclophasic) hormonotherapy comprises gestation and progestogen, wherein progestogen give in gestation existence and non-existent replacing.Disclosed therapy also provides estrogenic use in 2-4 days processes, takes place hemorrhage with prevention.
Detailed Description Of The Invention
The invention provides the combined therapy and the dosage that utilize contraceptive and one or more progestogenic medicine couplings.The present invention also provides Therapeutic Method and the dosage with these contraceptives and progestogenic medicine and estrogen (as ethinylestradiol) coupling.
Can give mammal with these therapies and combination, to cause contraception or to treat and/or prevent secondary amenorrhea, hemorrhage of functional disorder, leiomyoma of uterus, endometriosis; Polycystic ovary syndrome, uterine mucosa, ovary, mammary gland, colon, prostatic cancer and adenocarcinoma.Other purposes of the present invention comprise the stimulation food intake.This paper is used for the treatment of and/or prevents the purposes of above-mentioned situation or disease to comprise, continuous administration or regular discontinuous using according to the present invention make that effective dose minimum or side effect or periodicity menses are minimum.
Contraception purposes of the present invention comprises, with gestation and estrogen or progestogen or both couplings, is applied to (preferred oral) women of child-bearing age together.These dosage regimens should be carried out 28 days continuously, did not use progestogen, estrogen or gestation during this cycle final.
In header cycle 14-24 day, progestogen in these combinations can give separately or unite estrogen to give, the progestin dosage scope that gives is equivalent to about 35-150 microgram levonorgestrel every day on progestogenic activity, preferable about 35-100 microgram levonorgestrel every day that is equivalent to.Beginning to give separately gestation the day in cycle of 14-24 between day or unite estrogen to give gestation, continue 1-11 day then.Gestation in these combinations can every day the dosage of about 2-50 microgram give, estrogen can every day the dosage of about 10-35 microgram give.In oral administration, contain the packing of 28 tablets of tablets or medicine box and will be included in and not give the placebo tablet that gestation or progestogen or estrogenic those days give.
In a preferable embodiment of the present invention, can 18-21 day of 28 diurnal periodicitys separately or associating estrogen give progestogen of the present invention, then separately or associating estrogen give gestation, continue 1-7 day.
The estrogen that uses in compositions of the present invention and the preparation is ethinylestradiol preferably.
Progestogenic medicine useful among the present invention includes, but are not limited to: levonorgestrel, norgestrel, desogestrel, 3-ketone desogestrel, norethindrone, gestodene, SH 420, norgestimate, husky progesterone difficult to understand (osaterone), acetic acid cyproterone, trimegestone (trimegestone), dienogest, spirorenone (drospirenone), nomegestrol or (17-deacetylation) norgestimate in the wrong.The preferable progestogen that are used for the present invention's combination are levonorgestrel, gestodene and trimegestone.
Of the present invention in 28 diurnal periodicitys oral medicine comprise that pro-gave the progestogenic medicine separately on the 21st, its daily dose is equivalent to the levonorgestrel of about 35-100 microgram on progestogenic activity.Be about 2-50 milligram gestation chemical compound of the present invention giving daily dose 22-24 day then, then in 25-28 not administration of day or give placebo.Best is, each relevant active component of daily dose is merged in the single daily dose unit of combination 28 diurnal periodicity unit every day, totally 28 day units.
In another program, (a day unit dose is equivalent to about 35-150 microgram levonorgestrel on progestogenic activity can to give the progestogenic medicine in preceding 21 days jointly, preferably be equivalent to about 35-100 microgram levonorgestrel) and estrogen (as ethinylestradiol, day about 10-35 microgram of unit dose scope).Can give the gestation of the about 2-50 milligram of daily dose after this as mentioned above in 22-24 day, then in 25-28 not administration of day or give placebo.
Other schemes in the scope of the invention comprise: give progestogenic medicine and estrogen uniting 1-21 day, described progestogenic medicine is preferably levonorgestrel, the progestogenic activity of its daily dose is equivalent to about 35-100 microgram levonorgestrel, and the daily dose scope of described estrogen (as ethinylestradiol) is about the 10-35 microgram.Then, give gestation (2-50 milligram/day) and estrogen (as ethinylestradiol, its daily dose is about 10-35 microgram) uniting 22-24 day.In 25-28 day, not administration or give placebo.
The present invention also comprises the medicine box or the packing of the pharmaceutical preparation that is designed for scheme of the present invention.These medicine boxs should be designed in 28 diurnal periodicitys oral administration every day, preferably every day oral administration once, and organize, to show the single part of oral formulations will taking in the every day of 28 diurnal periodicitys or the combination of oral formulations.Preferably, each medicine box is included in the oral tablet that will take specified every day, and preferably a slice oral tablet will contain the daily dose of the various combinations of indicating.
According to such scheme, medicine box can contain in a kind of 28 days:
A) be used for the progestogenic medicine of the 14-21 daily dose unit of phase I, its progestogenic activity is equivalent to about 35-150 microgram levonorgestrel, and preferably progestogenic activity is equivalent to about 35-100 microgram levonorgestrel;
B) be used for the gestation chemical compound of the present invention of a 1-11 daily dose unit of second stage, the gestation chemical compound that daily dose is about the 2-50 milligram is contained in each daily dose unit; With
C) optional, be used for acceptable oral placebo on the materia medica of cycle residue day of phase III, wherein do not give gestation, progestogen or estrogen.
The preferable embodiment of this medicine box can comprise:
A) be used for the progestogenic medicine of 21 daily dose units of phase I, its progestogenic activity is equivalent to about 35-150 microgram levonorgestrel, and preferably progestogenic activity is equivalent to about 35-100 microgram levonorgestrel;
B) be used for the gestation chemical compound of the present invention of 3 daily doses of second stage 22-24 day, the gestation chemical compound of the about 2-50 milligram of daily dose is contained in each daily dose unit; With
C) acceptable oral placebo on the materia medica of optional 4 daily dose units that are used for the phase III is used for 25-28 day.
Another kind of 28 diurnal periodicity packaging schemes of the present invention or medicine box comprise:
A) be used for the 18-21 of phase I and contain progestogenic medicine and estrogenic daily dose unit, the progestogenic activity of progestogenic medicine is equivalent to about 35-150 microgram levonorgestrel, preferably progestogenic activity is equivalent to about 35-100 microgram levonorgestrel, is about the 10-35 microgram as the daily dose scope of estrogenic ethinylestradiol; With
B) 1-7 the daily dose that have that is used for second stage is about the daily dose unit of the gestation chemical compound of the present invention of 2-50 milligram; With
C) optional, be used for acceptable oral placebo on the 28 diurnal periodicitys residue 0-9 materia medica of every day day, wherein do not give progestogenic medicine, estrogen or gestation.
A preferable embodiment of above-mentioned medicine box can comprise:
A) be used for the progestogenic medicine and the estrogen of 21 daily dose units of phase I, the progestogenic activity of progestogenic medicine is equivalent to about 35-150 microgram levonorgestrel, preferably be equivalent to about 35-100 microgram levonorgestrel, be about the 10-35 microgram as estrogenic ethinylestradiol daily dose scope; With
B) be used for the gestation of 3 daily dose units of second stage 22-24 day, give dosage its every day and be about the 2-50 milligram; With
C) optional, be used for acceptable oral placebo on the materia medica of 4 daily dose units of phase III 25-28 every day day.
Another kind of 28 days packaging schemes of the present invention or medicine box comprise:
A) be used for the 18-21 daily dose unit of phase I, constituent parts contains progestogenic medicine of the present invention and ethinylestradiol, the daily dose of progestogenic medicine is equivalent to about 35-150 microgram levonorgestrel on progestogenic activity, preferably be equivalent to about 35-100 microgram levonorgestrel, ethinylestradiol daily dose scope is about the 10-35 microgram; With
B) be used for the 1-7 daily dose unit of second stage, the gestation of the present invention of the about 2-50 milligram of concentration and the concentration ethinylestradiol for about 10-35 microgram is contained in each daily dose unit; With
C) optional, be used for acceptable oral placebo on the 28 diurnal periodicitys residue 0-9 materia medica of every day day, wherein do not give progestogenic medicine, estrogen or gestation.
A preferable embodiment of above-mentioned packing or medicine box comprises:
A) be used for 21 daily dose units of phase I, constituent parts contains progestogenic medicine of the present invention and ethinylestradiol, the daily dose of progestogenic medicine is equivalent to about 35-150 microgram, the progestogenic activity of preferably about 35-100 microgram levonorgestrel, and the daily dose scope of ethinylestradiol is about 10-35 microgram; With
B) be used for 3 daily dose units of second stage 22-24 day, each dosage unit contains the gestation of the present invention of the about 2-50 milligram of concentration and the ethinylestradiol of the about 10-35 microgram of concentration; With
C) optional, be used for acceptable oral placebo on the materia medica of 4 daily dose units of phase III 25-28 every day day.
In above-mentioned each scheme and medicine box, preferably, the daily dose of each active constituents of medicine is fixed in the stage in each specific administration in the scheme.Should also be understood that described daily dose unit gives with described order, is second and the phase III successively after the phase I.For consistent with each scheme, it also is preferable that medicine box contains the described placebo that used last several days of cycle.In addition, each packing or medicine box should contain acceptable packing on the materia medica, and it has the sign corresponding to 28 diurnal periodicity every days, as known in the art the blister package of tape label or be with graduated administrator packing.
In this article, term contraceptive, gestation and progesterone receptor antagonist should be understood to synonym.Similarly, progestogen, progestogenic medicine and progesterone receptor agonist are understood as and have identical active chemical compound.
These dosages can be regulated, so that best therapeutic response to be provided.For example,, but give every kind of composition with several dosage that separate every day, or increase or reduce dosage in proportion according to the treatment situation.In the description of this paper, so-called " daily dose unit " also can be included in the dosage unit that separately give in the process every day in cycle.
The chemical compound of the present invention that can be used as the contraceptive in medicine box described herein, method and the scheme is those chemical compounds or its pharmaceutically acceptable salt with formula 1:
Wherein:
A and B respectively are the substituent groups that is selected from S, CH or N;
Condition is when A is S, and B is CH or N; Condition is
When B was S, A was CH or N;
With A and B can not be CH simultaneously;
With when A and B are N, a N can be randomly by C
1-C
6Alkyl replaces;
R
1And R
2Respectively be to be selected from following substituent group: H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
2-C
6The C of alkenyl, replacement
2-C
6Alkenyl, C
2-C
6The C of alkynyl, replacement
2-C
6Alkynyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
AOr NR
BCOR
A
Or R
1And R
2Condense formation:
A) the optional 3-8 unit spirocyclane basic ring that replaces preferably is a 3-6 unit spirocyclane basic ring; Or
B) the optional 3-8 unit volution alkene basic ring that replaces preferably is a 3-6 unit volution alkene basic ring; Or
C) choose the 3-8 unit volution that replaces wantonly, contain 1-3 hetero atom that is selected from O, S and N, preferably for containing 1-3 the first volution of heteroatomic 3-6;
R
ABe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
BBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
6The C of alkenyl, replacement
1-C
6Alkenyl, alkynyl or the alkynyl, the COR that replace
C
R
CBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
4Be the trisubstituted benzene ring that contains substituent X, Y and Z as follows:
X is selected from halogen, CN, C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3The C of alkylthio group, replacement
1-C
3Alkylthio group, C
1-C
3The C of aminoalkyl, replacement
1-C
3Aminoalkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 or 6 yuan of heterocycles, COR
D, OCOR
D, or NR
ECOR
D
R
DBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
EBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
Y and Z are selected from following substituent group: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
3Alkyl or C
1-C
3Alkylthio group;
Or
R
4Be 5 or 6 yuan of rings, contain 1,2 or 3 and be selected from following hetero atom O, S, SO, SO
2Or NR
5, and contain individual following substituent group: H, halogen, CN, the NO of respectively being selected from of 1-2
2, and C
1-C
3Alkyl, C
1-C
3Alkoxyl, C
1-C
3Aminoalkyl, COR
F, or NR
GCOR
F
R
FBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
GBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
5Be H or C
1-C
3Alkyl;
W is O or chemical bond.
Chemical compound or its pharmaceutically acceptable salt that those formulas I is arranged in the preferred gestation chemical compound of the present invention, wherein:
A and B respectively are the substituent groups that is selected from S, CH or N;
Condition is when A is S, and B is CH or N; Condition is
When B was S, A was CH or N;
With A and B can not be CH simultaneously;
With when A and B are N, a N can be randomly by C
1-C
6Alkyl replaces;
R
1Be H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
A, or NR
BCOR
A
R
2Be H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
2-C
6The C of alkenyl, replacement
2-C
6Alkenyl, C
2-C
6The C of alkynyl, replacement
2-C
6Alkynyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
A, or NR
BCOR
A
Or R
1And R
2Condense formation:
A) the optional 3-8 unit spirocyclane basic ring that replaces; Or
B) the optional 3-8 unit volution alkene basic ring that replaces; Or
C) the optional 3-8 unit volution that replaces contains 1-3 hetero atom that is selected from O, S and N;
R
ABe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
BBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
6The C of alkenyl, replacement
1-C
6Alkenyl, alkynyl or the alkynyl, the COR that replace
C
R
CBe H, C
1-C
4The C of alkyl, replacement
1-C
4The aryl of alkyl, aryl, replacement, C
1-C
4The C of alkoxyl, replacement
1-C
4Alkoxyl, C
1-C
4Aminoalkyl or the C that replaces
1-C
4Aminoalkyl;
R
4Be the trisubstituted benzene ring that contains substituent X, Y and Z as follows:
X is selected from halogen, CN, C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3The C of alkylthio group, replacement
1-C
3Alkylthio group, C
1-C
3The C of aminoalkyl, replacement
1-C
3Aminoalkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 yuan of heterocycles, COR
D, OCOR
D, or NR
ECOR
D
R
DBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
EBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
Y and Z are selected from following substituent group: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
3Alkyl or C
1-C
3Alkylthio group;
R
4Be 5 or 6 yuan of rings, contain 1,2 or 3 and be selected from following hetero atom O, S, SO, SO
2Or NR
5, and contain individual following substituent group: H, halogen, CN, the NO of respectively being selected from of 1-2
2, and C
1-C
3Alkyl, C
1-C
3Alkoxyl;
R
5Be H or C
1-C
3Alkyl;
W is O or chemical bond.
Chemical compound or its pharmaceutically acceptable salt that other preferred progesterone receptor antagonisies are those formulas I, wherein:
A and B respectively are the substituent groups that is selected from S, CH or N;
Condition is when A is S, and B is CH or N; With
When B was S, A was CH or N; With
A and B can not be CH simultaneously;
R
1=R
2And be selected from: C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, by R
1And R
2Condense the spiro cycloalkyl group that the 3-6 unit spirane structure of formation is constituted;
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl or COR
C
R
CBe H, C
1-C
4Alkyl or C
1-C
4Alkoxyl;
R
4Be the disubstituted benzenes ring that contains substituent X and Y as follows:
X is selected from following group, comprising: halogen, CN, C
1-C
3Alkoxyl, C
1-C
3Alkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 yuan of heterocycles or C
1-C
3Alkylthio group;
Y is the following substituent group of 4 ' or 5 ' be selected from, and comprising: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
4Alkyl, C
1-C
3Alkylthio group;
Or
R
4Be 5 yuan of rings of following structure
U is O, S or NR
5,
R
5Be H or C
1-C
3Alkyl or C
1-C
4CO
2Alkyl;
X ' is selected from following group: halogen, CN, NO
2, C
1-C
3Alkyl or C
1-C
3Alkoxyl;
Y ' is: H or C
1-C
4Alkyl;
Or
R
4Be 6 yuan of rings of following structure:
X
1Be N or CX
2
X
2Be halogen, CN or NO
2
W is O or chemical bond.
Chemical compound of the present invention can contain asymmetric carbon atom, and chemical compounds more of the present invention can contain one or more asymmetric centers, and therefore optical isomer and diastereomer can be arranged.Though formula I, II and III do not show with spatial chemistry, the present invention includes this type of optical isomer and diastereomer; And racemic and enantiomer-pure R and S stereoisomer that disassemble; And other mixture of R and S stereoisomer and their pharmaceutically acceptable salts.
Term used herein " alkyl " refers to straight chain and the saturated aliphatic hydrocarbon group that contains 1-8 carbon atom of side chain, is preferably and contains 1-6 carbon atom; " alkenyl " comprises straight chain and the branched hydrocarbyl that contains at least one carbon-carbon double bond and 2-8 carbon atom, preferably contains 1-6 carbon atom; " alkynyl " comprises straight chain and the branched hydrocarbyl that contains at least one carbon carbon triple bond and 2-8 carbon atom, preferably contains 2-6 carbon atom.
Term " alkyl of replacement ", " alkenyl of replacement " and " alkynyl of replacement " refer to by one or more are selected from abovementioned alkyl, alkenyl and alkynyl that following substituent group replaces at least: halogen, CN, OH, NO
2, amino, aryl, heterocycle, the aryl of replacement, the heterocycle of replacement, alkoxyl, aryloxy group, the alkoxyl of replacement, alkyl-carbonyl, alkyl carboxyl, alkyl amino, arylthio.These substituent groups can be connected on any carbon atom of alkyl, alkenyl or alkynyl group, but condition is this stable chemical part that connects and composes.
The term of this paper " aryl " refers to aromatic systems, can be monocycle or many aromatic rings condensed or that link together, thereby condenses or at least one part of connecting ring forms conjugated virtue system.Aromatic yl group can comprise (but being not restricted to): phenyl, naphthyl, xenyl, anthryl, tetralyl, phenanthryl.
Term " aryl of replacement " refers to be selected from the above-mentioned aryl that following group replaces by one or more: halogen, CN, OH, NO
2, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyl, aryloxy group, replacement alkoxyl, alkyl-carbonyl, alkyl carboxyl, alkyl amino or arylthio.
Term used herein " heterocycle " refers to stable 4-to 7-unit monocycle or stable multi-ring heterocycle, can be saturated, part is undersaturated or undersaturated, and by carbon atom be selected from a following 1-4 hetero atom and constitute: N, O and S atom.N and S atom can be oxidized.Heterocycle also can comprise any multi-ring, and wherein arbitrary above-mentioned heterocycle can condense in aromatic ring.This heterocycle can be connected in any hetero atom or carbon atom, but the structure that is generated must be chemically stable.These heterocycles comprise as oxolane, piperidyl, piperazinyl, 2-oxo-piperidine base, azepines base, pyrrolidinyl, imidazole radicals, pyridine radicals, pyrazinyl, pyrimidine radicals, pyridazinyl, oxazolyl, isoxazolyl, morpholinyl, indyl, quinolyl, thienyl, furyl, benzofuranyl, benzothienyl, thio-morpholinyl, thio-morpholinyl sulfoxide and isoquinolyl.
Term used herein " heterocycle of replacement " refers to have following one or more substituent above-mentioned heterocycle: halogen, CN, OH, NO
2, amino, alkyl, replacement alkenyl, alkynyl, alkoxyl, aryloxy group, alkoxyl, alkyl-carbonyl, alkyl carboxyl, alkyl amino or the arylthio of replacement of alkyl, cycloalkyl, alkenyl, replacement.Term used herein " alkoxyl " refers to the OR group, and wherein R is the alkyl of alkyl or replacement.The term of this paper " aryloxy group " refers to the OR group, and wherein R is the aryl of aryl or replacement.The term of this paper " alkyl-carbonyl " refers to the RCO group, and wherein R is the alkyl of alkyl or replacement.The term of this paper " alkyl carboxyl " refers to the COOR group, and wherein R is the alkyl of alkyl or replacement.Term " aminoalkyl " refers to secondary amine and tertiary amine, and wherein the alkyl of alkyl or replacement can be identical or different, and junction point be on nitrogen-atoms.Term used herein " alkylthio group " refers to the SR group, and wherein R is the alkyl of alkyl or replacement.Term " halogen " refers to Cl, Br, F and I element.
Can be by following flow preparation gestation chemical compound of the present invention:
The cyclic carbramates derivant
The method for preparing the thiphene ring carbamate derivatives
A. following flow process 1 has been described the method for synthesizing thiofuran cyclic carbramates chemical compound:
Flow process 1
So can be by the list of references flow process that comprises Gewald reaction (see " Comprehenisve HeterocyclicChemistry II; 1982-1995 literature review; people such as A.R.Katritsky the 2nd volume; the 639th page) preparation aminothiophene ester 2; promptly in the methanol that refluxes, suitably the aromatics acetaldehyde that replaces reacts (flow process 1) with sulfur and malonic methyl ester nitrile.2-amino group and suitable chloro-formate or carbonate reaction generate the amine of protecting 3.This can be by allowing 2 (to realize as methylchloroformate, ethyl chloroformate, allyl chlorocarbonate, 2-(trimethyl silyl) ethyl chloroformate or Bis(tert-butoxycarbonyl)oxide with chloro-formate or carbonic acid ester derivative in solvent (as benzene,toluene,xylene, dichloromethane, oxolane or pyridine).Can be under inert atmosphere (nitrogen or argon), 0 ℃ is carried out this reaction to the solvent refluxing temperature, and may need to exist alkali (as 4-dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine).Under the inert atmosphere (nitrogen or argon); 0 ℃ of suitable temperature to the solvent refluxing temperature; allow amino-compound 3 reactions of organometallic reagent (as Grignard reagent, alkyl or aryl zincon, alkyl or aryl lithium reagent) and protection in the atent solvent (as oxolane, diethyl ether), can generate the tertiary alcohol 4.Then chemical compound 4 is placed alkali condition to allow the ring closure obtain cyclic carbramates derivant 5.Appropriate condition comprises: handle 4 with alkali (as potassium hydroxide) in appropriate solvent (as the tetrahydrofuran solution of ethanol or potassium tert-butoxide).Can be under inert atmosphere (nitrogen or argon), 0 ℃ of reflux temperature to solvent carries out this reaction.
Flow process 2
In addition, can remove under the condition of carbamic acid ester protecting group being suitable for, this group of removing in 4 obtains 6 (flow processs 2).Subsequently in suitable solvent (as oxolane, dichloromethane, benzene etc.), with 6 ring closure, also will obtain 5 with reagent (as phosgene, carbonyl dimidazoles or DMC dimethyl carbonate).
Flow process 3
In addition, also chemical compound 4 dehydrations can be obtained different acryloyl derivative 7 (flow process 3).The condition that is suitable for dewatering is for using reagent such as acetic anhydride, mesyl chloride, p-toluenesulfonyl chloride or trifluoromethanesulfchloride chloride or anhydride in solvent (as pyridine, oxolane, dichloromethane or benzene).Can be under inert atmosphere (nitrogen or argon), 0 ℃ is carried out this reaction to the solvent refluxing temperature, and may need to exist alkali (as 4-dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine).Contact with acid condition 7, will make the ring closure obtain 5.Appropriate condition is to use acid as p-methyl benzenesulfonic acid, methanesulfonic acid or camphorsulfonic acid in appropriate solvent (as dichloromethane, benzene, toluene or oxolane).Can be under inert atmosphere (nitrogen or argon), 0 ℃ of reflux temperature to solvent carries out this reaction.
Flow process 4
Flow process 4 has shown and has prepared 5 another kind of method.Under the inert atmosphere (nitrogen or argon), 0 ℃ of suitable temperature to the solvent refluxing temperature uses organometallic reagent such as Grignard reagent, alkyl or aryl zincon, alkyl or aryl lithium reagent to handle above-mentioned chemical compound 8 (M.Sugiyama, T.Sakamoto in atent solvent (as oxolane, diethyl ether), K.Tabata, K.Endo, K.Ito, M.Kobayashi, H.Fukiumi, Chem.Pharm.Bull., 37 (8): 2091 (1989)), generate the tertiary alcohol 9.Chemical compound 9 can be placed alkali condition then, allow the ring closure generate cyclic carbramates derivant 10.Appropriate condition is included in the tetrahydrofuran solution of atent solvent such as ethanol or potassium tert-butoxide with alkali such as potassium hydroxide treatment 10.Can be under inert atmosphere (nitrogen or argon), 0 ℃ of reflux temperature to solvent carries out this reaction.Chemical compound 10 can be changed into the derivant 11 of bromination then.Appropriate condition is included in the solvent (as dichloromethane, oxolane or acetic acid) and handles with bromine or N-bromine butanimide.Can be under inert atmosphere (nitrogen or argon), 0 ℃ of reflux temperature to solvent carries out this reaction when having additive such as silica gel.With relief 11 and aryl or heteroaryl boric acid, boric anhydride or the reaction of trialkyl aryl stannane, generate required biaryl compound 5.Under the inert atmosphere (nitrogen or argon), 0 ℃-solvent refluxing temperature, in solvent such as acetone, ethanol, benzene, toluene or oxolane, exist palladium catalyst as four (triphenylphosphines) close-carry out this reaction when palladium (O) or acid chloride, also may need additive such as sodium carbonate, cesium fluoride or potassium phosphate.
Flow process 5
In addition, also can be in atent solvent (as oxolane), low temperature with reagent such as lithium alkylide or Lithamide. and 10 (flow process 5) reaction, changes into boric acid 12 (M=B (OH) down then under the effect of methyl borate. or triisopropyl borate ester
2), or by changing into the aryl stannane with trimethyltin chloride or two (tin trimethyl).When having palladium catalyst (closing-palladium (0) or acid chloride) subsequently as four (triphenylphosphines), allow 12 with the reaction of aryl or heteroaryl bromine or iodine, may need additive such as sodium carbonate, cesium fluoride or potassium phosphate, convert it into required thiophene carbamate 5 then.
B. following flow process 6 has shown the method for synthesizing thiofuran cyclic carbramates chemical compound:
Flow process 6
Press flow process (" Comprehenisve Heterocyclic Chemistry II; 1982-1995 literature review; people such as A.R.Katritsky the 2nd volume; the 639th page) preparation aminothiophene chemical compound 15 (flow processs 6) of list of references; comprise N; the aromatics ketone 13 that the dinethylformamide solution-treated suitably replaces, generate chlorine cyano group alkene derivatives 14 with phosphorus oxychloride.Allow 14 with the methyl thioglycolate reaction that contains in the methanol of Feldalat NM, generate crucial aminothiophene carboxylate starting material.Allow 2-amino with suitable chloro-formate or carbonate reaction, generate protected amine 16.This can finish with 15 reactions with chloro-formate or carbonic acid ester derivative (as methylchloroformate, ethyl chloroformate, allyl chlorocarbonate, 2-(trimethyl silyl) ethyl chloroformate or Bis(tert-butoxycarbonyl)oxide) by in solvent (as benzene,toluene,xylene, dichloromethane, oxolane or pyridine).Can be under inert atmosphere (nitrogen or argon), 0 ℃-solvent refluxing temperature is carried out this reaction, also may need alkali such as 4-dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine.At inert atmosphere (nitrogen or argon), the proper temperature between 0 ℃-solvent refluxing temperature is handled the amino-compound of protecting 16 with organometallic reagent (as Grignard reagent, alkyl or aryl zincon, alkyl or aryl lithium reagent), generates the tertiary alcohol 17.Then chemical compound 17 is placed alkali condition, make the closed cyclic carbramates derivant 18 that generates of ring.The condition that is fit to is included in the solvent (as the tetrahydrofuran solution of ethanol or potassium tert-butoxide) and handles 4 with alkali (as potassium hydroxide).Can under inert atmosphere (nitrogen or argon), carry out this reaction in the reflux temperature of 0 ℃-solvent.
Flow process 7
In addition, also can remove under the condition of carbamic acid blocking group being suitable for, remove 17 carbamic acid blocking group, generate 19 (flow processs 7).In suitable solvent (as oxolane, dichloromethane, benzene etc.), handle 19 subsequently, make its closed loop generate 18 with reagent (as phosgene, carbonyl dimidazoles or DMC dimethyl carbonate).
Flow process 8
In addition, chemical compound 17 dehydrations are generated different acryloyl derivative 20 (flow process 8).The condition that is fit to dehydration is included in the solvent (as pyridine, oxolane, dichloromethane or benzene) with reagent such as acetic anhydride, mesyl chloride, paratoluensulfonyl chloride or trifluoromethanesulfchloride chloride or anhydride.To the solvent refluxing temperature, carry out this reaction at inert atmosphere (nitrogen or argon) 0, may need to exist alkali such as 4-dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine.Place acid condition with 20, make the ring closed loop generate 18.Appropriate condition is included in uses acid as p-methyl benzenesulfonic acid, methanesulfonic acid or camphorsulfonic acid in the solvent (as dichloromethane, benzene, toluene or oxolane).Can carry out this reaction to the solvent refluxing temperature for following 0 ℃ at inert atmosphere (nitrogen or argon).
Flow process 9
Flow process 9 has shown other approach of synthetic 18.As H.Fukiumi, M.Sugiyama, T.Sakamoto, Chem.Pharm.Bull., 37 (5): 1197 (1989) is described, 0 ℃ of inert atmosphere (nitrogen or argon) proper temperature is handled above-mentioned chemical compound 21 with organometallic reagent (as Grignard reagent, alkyl or aryl zincon, alkyl or aryl lithium reagent) to the solvent refluxing temperature in atent solvent (oxolane, diethyl ether), generate the tertiary alcohol 22.Then chemical compound 22 is placed alkali condition, obtain cyclic carbramates derivant 23 with closed loop.Appropriate condition is included in the solvent (as the tetrahydrofuran solution of ethanol or potassium tert-butoxide) and handles 22 with alkali (as potassium hydroxide).Can be under inert atmosphere (nitrogen or argon), 0 ℃ to the solvent refluxing temperature, carries out this reaction.Then chemical compound 23 is changed into the derivant 24 of bromination.Appropriate condition is to handle with bromine or N-bromine butanimide in solvent (as dichloromethane, oxolane or acetic acid).Can be under inert atmosphere (nitrogen or argon), 0 ℃-solvent refluxing temperature is carried out this reaction when having additive (as silica gel).With aryl or heteroaryl boric acid, boric anhydride or trialkyl aryl stannane and 24 reactions, generate required biaryl compound 18 subsequently.Can be in inert atmosphere (nitrogen or argon) solvent (as acetone, ethanol, benzene, toluene or oxolane) 0 ℃ to the solvent refluxing temperature, carry out this reaction when having palladium catalyst (closing-palladium (O) or acid chloride), may need additive such as sodium carbonate, cesium fluoride or potassium phosphate as four (triphenylphosphines).
Flow process 10
In addition, also can in atent solvent (as oxolane),, under the effect of methyl borate. or triisopropyl borate ester, change into boric acid 25 (M=B (OH) then at low temperatures with lithium alkylide or lithium amide-treated 23 (flow process 10)
2), or by changing into the aryl stannane with trimethyltin chloride or two (tin trimethyl) reaction.Exist palladium catalyst to react with aryl or heteroaryl bromine or iodine and 25 when (as closing-palladium (0) or acid chloride) subsequently as four (triphenylphosphines), may need additive (as sodium carbonate, cesium fluoride or potassium phosphate), change into required thiphene ring carbamate 18 then.
C. following flow process 11 has shown the method for synthesizing thiofuran sulfo-cyclic carbramates chemical compound 26 and 27:
Flow process 11
Phosphorus pentasulfide in the available backflow pyridine handles 5 and 18 respectively, directly obtains thiophenic sulfur for cyclic carbramates 26 and 27.In addition, the Lawesson reagent ([2,4-two (4-methoxyphenyl)-1,3-dithio-2,4-two phosphetane-2,4-disulphide]) that also can be used in the backflow pyridine handles 5 and 18 respectively, generates 26 and 27.
The method for preparing the thiazole ring carbamate derivatives
The following method for preparing the thiazole ring carbamate compounds that shown:
Flow process 12
So, pressing document flow process B.Golankiewicz and P.Januszczyk, Tetrahedron, 41:5989 (1985) they are flow process 12 preparation thiazoles 28.With amine 28 and suitable chloro-formate or carbonate reaction, generate the amine 29 of protection.This can allow chemical compound 28 and chloro-formate or carbonic acid ester derivative (realize as methylchloroformate, ethyl chloroformate, allyl chlorocarbonate, 2-(trimethyl silyl) ethyl chloroformate or Bis(tert-butoxycarbonyl)oxide reaction by in solvent (as dichloromethane, THF, benzene, dimethylbenzene or pyridine).Can carry out this reaction in 0 ℃-solvent refluxing temperature of inert atmosphere (nitrogen or argon), may need to exist alkali such as 4-dimethylaminopyridine, triethylamine, pyridine or diisopropyl ester ethamine.Inert atmosphere (nitrogen or argon) following 0 ℃ to the proper temperature between the solvent refluxing temperature, with the reaction of the organometallic reagent (as Grignard reagent, alkyl or aryl zincon, alkyl or aryl lithium reagent) in chemical compound 29 and the atent solvent (as THF, ether), generate alcohol 30.Then chemical compound 30 is placed to make under the closed alkali condition of ring, generate cyclic carbramates derivant 31.Appropriate condition is included in the solvent (as ethanol) and handles chemical compound 30 with alkali (as potassium hydroxide).Under inert atmosphere (nitrogen or argon), 0 ℃ is carried out this reaction to the solvent refluxing temperature.
Flow process 13
In addition; as T.W.Greene and P.G.M.Wuts (at " blocking group in the organic synthesis "; second edition; Wiley-Interscience (1991)) described in; can be suitable for removing under the condition of carbamic acid ester protecting group; remove the carbamic acid ester protecting group of chemical compound 30, generate chemical compound 32.In appropriate solvent (as THF, dichloromethane, benzene etc.), use reagent (as phosgene, carbonyl dimidazoles or DMC dimethyl carbonate) with chemical compound 32 closed loops subsequently, also can generate chemical compound 31.
Flow process 14
In addition, if chemical compound 30 is tertiary alcohols, then its dehydration can be generated different acryloyl derivative 33 (flow process 3).The condition that is adapted to dewater is to use reagent such as acetic anhydride, mesyl chloride, paratoluensulfonyl chloride or trifluoromethanesulfchloride chloride or anhydride in solvent (as pyridine, THF, dichloromethane or benzene).Can carry out this reaction to the solvent refluxing temperature 0 ℃ of inert atmosphere (nitrogen or argon), may need to exist alkali such as 4-dimethylaminopyridine, triethylamine, pyridine or diisopropylethylamine.Chemical compound 33 is placed acid condition, make the ring closed loop generate chemical compound 31.Appropriate condition is to use acid as p-methyl benzenesulfonic acid, methanesulfonic acid or camphorsulfonic acid in solvent (as dichloromethane, benzene, toluene or THF), and carries out this reaction in 0 ℃-solvent refluxing temperature of inert atmosphere (nitrogen or argon).
Flow process 15
Chemical compound 31 can be changed into bromide 34 in the flow process 15.The condition that is fit to is to contact with bromine or N-bromine butanimide in solvent (as dichloromethane, THF or acetic acid), to the solvent refluxing temperature, carries out this reaction 0 ℃ of inert atmosphere (nitrogen or argon) when having additive (as silica gel).With chemical compound 34 and aryl or heteroaryl boric acid, boric anhydride or the reaction of trialkyl aryl stannane, generate required biaryl compound 35 subsequently.Can be in solvent (as acetone, ethanol, benzene, toluene or THF) 0 ℃ of inert atmosphere (nitrogen or argon) to the solvent refluxing temperature, carry out this reaction when having palladium catalyst (closing-palladium (0) or acid chloride), also may need additive such as sodium carbonate, cesium fluoride or potassium phosphate as four (triphenylphosphines).
Flow process 16
In addition, also can handle chemical compound 31, under the effect of methyl borate. or triisopropyl borate ester, change into boric acid (M=B (OH) then at the reagent (as lithium alkylide or lithium amide) that low temperature is used in the atent solvent (as THF)
2) 36, or under trimethyltin chloride or two (tin trimethyl) effect, changing into aryl stannane (flow process 16).Exist palladium catalyst to close-when palladium (0) or acid chloride, react subsequently, also may need additive such as sodium carbonate, cesium fluoride or potassium phosphate, thereby change into required chemical compound 35 with aryl or heteroaryl bromide or iodide as four (triphenylphosphines).
Amide derivatives
The method for preparing the amide thiophene derivant
Following flow process 17 has shown the method for preparing thiophene derivant:
Flow process 17
So amide 37 can be changed into carbamate (as t-butyl carbamate as described in preparation in the flow process 1 is during chemical compound 2).Ester hydrolysis 38 in the room temperature alkali condition (as Lithium hydrate in THF or methanol or sodium hydroxide) generates acid 39.Realize when (promptly have pure thionyl chloride or oxalyl chloride or thionyl chloride in solvent such as dichloromethane or oxalyl chloride, and contain the N of additive such as catalytic amount, dinethylformamide) that in standard conditions acid 39 changes into acid chloride 40.Then in atent solvent (as THF or dichloromethane) with chemical compound 40 and Azimethylene. or trimethyl silyl diazomethane reaction, when having silver oxide (I) then product diazo ketone 41 is reset, generate acid 42.Remove the condition (as acid condition) of protectiveness carbamate-functional at specificity and handle chemical compound 42 down, closed loop generates chemical compound 43 then.Inert atmosphere (nitrogen or argon) at-78 ℃ to the temperature between solvent boiling point, in solvent (as THF), alkali condition is (as existing N, N, N, butyl lithium during the N-tetra-methylenedimine) under,, generates alkylating derivant 44 with alkylating agent (as alkiodide, alkyl bromide, alkyl toluene sulphonic acid ester or alkyl methanesulfonates or dialkyl group iodide, dialkyl group bromide, dialkyl group tosylate or dialkyl group methanesulfonates) and chemical compound 43 reactions.
The method for preparing thiazole
Following flow process 18 has shown the method for preparing thiazole.
Flow process 18
Room temperature is in THF or methanol, and alkali condition (as sodium hydroxide or Lithium hydrate) ester hydrolysis 29 generates acid 45., realize acid 45 is changed into acid chloride 46 when (as having pure thionyl chloride or oxalyl chloride or thionyl chloride in solvent such as dichloromethane or oxalyl chloride, and containing the N of additive such as catalytic amount, dinethylformamide) in standard conditions.Then in atent solvent (THF or dichloromethane) with chemical compound 46 and Azimethylene. or three silicyl diazomethane reactions, when having silver oxide (I) then product diazo ketone 47 reset and generates acid 48.Remove the condition (as acid condition) of protectiveness carbamate-functional at specificity and handle chemical compound 48 down, closed loop generates heterocyclic compound 49 then.Inert atmosphere (nitrogen or argon) at-78 ℃ to the temperature between solvent boiling point, in solvent (as THF), alkali condition is (as existing N, N, N, butyl lithium during the N-tetra-methylenedimine) under,, generates alkylating heterocyclic compound 50 with alkylating agent (as alkiodide, alkyl bromide, alkyl toluene sulphonic acid ester or alkyl methanesulfonates or dialkyl group iodide, dialkyl group bromide, dialkyl group tosylate or dialkyl group methanesulfonates) and chemical compound 49 reactions.Chemical compound 50 can be changed into bromide 51 then.Suitable condition is to contact with bromine or N-bromine butanimide in the solvent (as dichloromethane, THF or acetic acid), inert atmosphere (nitrogen or argon) following 0 ℃ between the solvent refluxing temperature, carry out this reaction when having additive (as silica gel).With relief chemical compound 51 and aryl or heteroaryl boric acid, boric anhydride or the reaction of trialkyl aryl stannane, generate required biaryl compound 52.0 ℃ of inert atmosphere (nitrogen or argon) is between the solvent refluxing temperature, when having palladium catalyst (closing-palladium (0) or acid chloride) as four (triphenylphosphines), in solvent (as acetone, ethanol, benzene, toluene or THF), carry out this reaction, also may need additive such as sodium carbonate, cesium fluoride or potassium phosphate.Handle 52 with the phosphorus pentasulfide in the backflow pyridine and can directly obtain 40 thione derivatives-chemical compound 53.In addition, the Lawesson agent treated 52 in the also available backflow pyridine generates 53.
Gestation chemical compound in the present invention prescription can by pharmaceutically or the acceptable acid of physiology or the deutero-salt form of alkali use.These salt comprise the salt that (but being not restricted to) and following mineral acid form: example hydrochloric acid, sulphuric acid, nitric acid, phosphoric acid, organic acid then refer to acetic acid, oxalic acid, succinic acid and maleic acid.Other salt comprise the salt with alkali metal or alkaline-earth metal, as sodium, potassium, calcium or magnesium, with the form (when giving this form, can change into active part in vivo) of " prodrug " of ester, carbamate or other routines.
These Therapeutic Method can be used for contraception, or be used for the treatment of and/or prevent the method for secondary amenorrhea, hemorrhage of functional disorder, leiomyoma of uterus, endometriosis, polycystic ovary syndrome and uterine mucosa, ovary, mammary gland, colon and prostatic cancer and adenocarcinoma, or periodically menstrual bleeding or side effect minimize.Other purposes of the present invention comprise the stimulation food intake.
When blended chemical compound is used for such use; they can with one or more pharmaceutically acceptable carrier or mixed with excipients; as solvent, diluent etc., and can following form oral administration: tablet, capsule, dispersive powder, granule or suspension (containing 0.05-5% suspending agent according to appointment), syrup (containing sugar) and elixir (containing 20-50% ethanol according to appointment) etc. or carry out parenteral with sterile injectable solution or form of suspension (containing the 0.05-5% suspending agent of having an appointment in the medium waiting to ooze) just like 10-50%.These pharmaceutical preparatioies can contain just like with the blended about 25-90% active component of carrier, be about usually between 5%-60% (weight).
Can give these reactive compounds by oral and intravenous, intramuscular or subcutaneous route.Solid-state carrier comprises: starch, lactose, calcium hydrogen phosphate, microcrystalline Cellulose, sucrose and kaolin, and liquid carrier comprises: sterilized water, Polyethylene Glycol, nonionic surfactant and edible oil (as Semen Maydis oil, Oleum Arachidis hypogaeae semen and Oleum sesami), as long as be adapted to the characteristic of active component and required form of medication.Normally used adjuvant comprises as flavoring agent, pigment, antiseptic and antioxidant such as vitamin E, vitamin C, BHT and BHA in pharmaceutical compositions.
From being easy to preparation and administration, preferred pharmaceutical composition is a solid-state composition, especially the capsule of tablet and hard filling or liquid filling.The oral administration of chemical compound is preferred.
But these reactive compounds are parenteral or intraperitoneal administration also.The solution or the suspension that also can in the water that suitably is mixed with surfactant (as hydroxypropyl cellulose), prepare these reactive compounds (free alkali or pharmaceutically acceptable salt).Also can in glycerol, liquid, Polyethylene Glycol and their mixture in oil, prepare dispersion liquid.Under common storage and service condition, contain antiseptic in these preparations to prevent growth of microorganism.
The medicament forms that is adapted to inject comprises aseptic aqueous solution or dispersion liquid and aseptic powder (being used for temporarily preparing aseptic injectable solution or dispersion liquid).In all situations, these forms must be aseptic and must be that fluid is to be easy to the use of syringe.Under manufacturing and condition of storage must be stable, and must be able to resist the pollution effect of microorganism (as antibacterial and fungus).Carrier can be solvent or disperse medium, contains just like water, ethanol (as glycerol, propylene glycol and liquid polyethylene glycol), their suitable mixture and vegetable oil.
Following non-limiting example has illustrated the preparation of The compounds of this invention 5.
Embodiment 1
6-(3-chlorphenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno [2,3-d] [1,3] oxazine-2-ketone
2-(3-benzyl chloride base) acetaldehyde
Anhydrous CH at the 3-chlorostyrene
2Cl
2(10.0g dropwise adds the Pb (OAc) that stirs in 25 ℃ of solution 72.15mmol)
4(35.2g, trifluoroacetic acid 79.4mmol) (150ml) solution.Interpolation in 30 minutes finishes, and then stirs 30 minutes, and reaction is finished, and this mixture is toppled in the entry, and ether (3X) extracts, and uses saturated NaHCO
3The organic layer that solution, water washing merge, dry (MgSO4) is concentrated into the 15ml volume, and is used for following reaction rapidly.
2-amino-5-(3-chloro-phenyl)-thiophene-3-carboxylate methyl ester
In the methanol solution of the crude aldehyde of above-mentioned preparation, add sulfur (2.55g, 79.44mmol), malonic methyl ester nitrile (7.88g, 79.44mmol) and morpholine (6.92g, mixture 79.44mmol) was with this reaction mixture refluxed 16 hours.The unreacted sulfur of elimination, evaporated filtrate obtains black residue.With this residue of ether extraction, use H
2The O washing.From ether/hexane (1: 5) crystallization, obtain white crystal (3.85g, 14.3mmol, 50%), mp 85-87 °.
1H NMR (DMSO-d
6) δ 3.75 (s, 3H), 7.18-7.27 (m, 1H), 7.31-7.42 (m, 3H), 7.53 (s, 1H), 7.62 (s, 1H); MS (+APCI) m/z268 (M+H); C
12H
10ClNO
2S analyzes straight: C, 53.83, H, 3.76, N, 5.23.Measured value: C, 53.57, H, 3.37, N, 5.00.
2-allyloxy carbonyl ammonia base-5-(3-chloro-phenyl)-thiophene-3-carboxylate methyl ester
Under the room temperature nitrogen, 2-amino-5-(3-chloro-phenyl)-thiophene-3-carboxylate methyl ester (2g, 7.5mmol) anhydrous 1, add in 2-dichloroethanes (50ml) solution allyl chlorocarbonate (1.6ml, 15.1mmol).This reactant mixture of reflux is 18 hours under the nitrogen, is cooled to room temperature, handles with saturated sodium bicarbonate aqueous solution (100ml).Separately organic layer is used dichloromethane (3 * 20ml) extraction water layers.Organic layer and dry (MgSO4) with salt water washing merging.Remove desolvate after, fast the silicagel column purification (hexane: ethyl acetate/7: 1) residue obtains being the inferior title compound (2.14g, 81%) of pale solid:
1H-NMR (DMSO-d
6) δ 10.2 (s, 1H), 7.73 (t, 1H, J=1.7Hz), 7.66 (s, 1H), 7.57 (dt, 1H, J=7.7,1.7Hz), 7.41 (t, 1H, J=7.7Hz), 7.34 (dt, 1H, J=6.8,1.6Hz), 6.01 (m, 1H), 5.41 (dd, 1H, J=7.3,1.6Hz), 5.29 (dd, 1H, J=10.5,1.3Hz), 4.74 (d, 2H, J=5.5Hz), 3.84 (s, 3H).C
16H
14ClNO
4S assay value: C, 54.63, H, 4.01, N, 3.98.Measured value: C, 54.56, H, 3.92, N, 3.89.
Under the room temperature nitrogen, 2-allene oxygen base (allenoxy) carbonylamino-5-(3-chloro-phenyl)-thiophene-3-carboxylate methyl ester (0.1g, add in anhydrous THF solution 0.28mmol) methyl-magnesium-bromide (the 3.0M diethyl ether solution, 1.5ml, 4.5mmol).Room temperature nitrogen stirs after 20 minutes down, handles this reactant mixture with saline (10ml), adds 1N HCl solution (5ml) then.Add ethyl acetate (20ml), separately organic layer washs the MgSO4 drying with saline (5ml).Except that after desolvating, (silica gel, hexane: ethyl acetate/5: 1) purification residue, the methanol that obtains need not to be further purified and the qualitative next step that is directly used in the flash chromatography post.
Under the room temperature nitrogen, be stirred in the above-mentioned crude methanol in the ethanol, the mixture overnight of potassium hydroxide (excessive).Add cold this reaction solution of 1N HCl acidified aqueous solution then.Add ethyl acetate (20ml), separately organic layer washs with saline (5ml), dry (MgSO4).Remove desolvate after, (hexane: ethyl acetate/2: 1) purification residue obtains being the title compound (16mg, 19% liang of step) of pale solid: mp 149-150 ℃ to the silicagel column purification;
1H-NMR (DMSO-d
6) δ 10.69 (s, 1H), 7.64 (t, 1H, J=1.8Hz), 7.49 (s, 1H), 7.47 (dt, 1H, J=7.7,1.4Hz), 7.39 (t, 1H, J=7.8Hz), 7.29 (dt, 1H, J=7.8,1.3Hz), 1.61 (s, 6H).MS(EI)m/z?293/295(M
+)。C
14H
12ClNO
2S assay value: C, 57.24, H, 4.12, N, 4.77.Measured value: C, 57.27, H, 4.25, N, 4.66.
Embodiment 2
6-(3-chlorphenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno [3,2-d] [1,3] oxazine-2-ketone
3-chloro-3-(3-chloro-phenyl)-acrylonitrile
POCl3 solution slowly is added in the dry DMF, for the time 20 minutes, and with temperature maintenance about 30 ℃.The anhydrous DMF solution of 3 '-chloracetophenone is added in the above-mentioned solution, allows reaction temperature rise to about 50 ℃.In this reaction solution, add the HCl azanol in batches, for the time 1 hour.Add 500ml volume water and form precipitation, stirred 1 hour, with B ü chner funnel collecting precipitation, H
2The O washing, drying obtains yellow crystalline chemical compound, mp 60-62 ℃.
1H NMR (DMSO-d
6) δ 1.60 (s, 6H), 7.30 (d, 1H, J=8.41Hz), 7.41 (d, 1H, J=8.41Hz), 10.47 (s, 1H); MS (+APCI) m/z 213 (M+H); C
9H
9ClN
2O
2Assay value: C, 50.84, H, 4.27, N, 13.17.Measured value: C, 50.99, H, 4.28, N, 12.98
3-amino-5-(3-chloro-phenyl)-thiophene-2-carboxylic acid methyl ester
The sodium grain is slowly dropped into methanol solution form NaOMe, when in methanol solution, adding the thiol methyl acetate then and being 20 minutes.Slowly add the methanol solution of 3-chloro-3-(3-chloro-phenyl)-acrylonitrile, refluxed then 1 hour.Reactant mixture is cooled to room temperature, this methanol is concentrated into 100ml, add 200ml water, stirred 30 minutes, collect yellow mercury oxide, wash several times with water, obtain 92-95 ℃ of yellow crystalline chemical compound mp.
1H NMR (DMSO-d
6) δ 1.60 (s, 6H), 7.30 (d, 1H, J=8.41Hz), 7.41 (d, 1H, J=8.41Hz), 10.47 (s, 1H); MS (+APCI) m/z 213 (M+H); C
9H
9ClN
2O
2Assay value: C, 50.84, H, 4.27, N, 13.17.Measured value: C, 50.99, H, 4.28, N, 12.98.
3-allyloxy carbonyl ammonia base-5-(3-chloro-phenyl)-thiophene-2-carboxylic acid methyl ester
(15g adds allyl chlorocarbonate (8.10g, toluene 67.2mmol) (5.0ml) solution, this reaction solution of reflux 3 hours in the solution of toluene 56.0mmol) (200ml) at 3-amino-5-(3-chloro-phenyl)-thiophene-2-carboxylic acid methyl ester.Remove (strip down) toluene, collect crystal, obtain yellow crystals chemical compound, mp 101-103C with the ether/hexane washing.
1H NMR (DMSO-d
6) δ 3.85 (s, 3H), 4.68-4.71 (d, 2H, J=5.46Hz), 5.26-5.30 (dd, 1H, J=1.35,9.84Hz), 5.36-5.42 (dd, 1H, J=1.57,15.68Hz), 5.96 (m, 2H), 7.50-7.52 (m, 2H), and 7.67-7.71 (m, 1H), 7.79 (s, 1H), 8.10 (s, 1H); MS (+APCI) m/z 352 (M+H); C
16H
14ClNO
4S assay value: C, 54.63, H, 4.01, N, 3.97.Measured value: C, 54.05, H, 4.17, N, 3.84.
[5-(3-chloro-phenyl)-2-(1-hydroxyl-1-methyl-ethyl)-thiene-3-yl-]-allyl carbamate
(5.3g in the solution of anhydrous THF (30ml) 15.1mmol), adds ether (20.1ml, 60.24mmol) solution of 3.0M MeMgI to room temperature at 3-allyloxy carbonyl ammonia base-5-(3-chloro-phenyl)-thiophene-2-carboxylic acid methyl ester.After 30 minutes, use H
2Saturated NH is used in slowly cancellation reaction of O (10ml)
4OH (100ml) handles, and ether (200ml) extracts, the salt water washing, and dry (MgSO4) concentrates and chromatography (hexane/ether, 1: 4): mp 60-61 ℃;
1H NMR (DMSO-d
6) δ 1.52 (s, 6H), 4.59-4.61 (d, 2H, J=5.35Hz), 5.22-5.36 (m, 2H), 5.91-6.04 (m, 2H), 7.33-7.67 (m, 5H), 8.89 (s, 1H); MS (EI) m/z 351/353 (M+H); C
L7H
18ClNO
3S assay value: C, 58.03, H, 5.16, N, 3.98.Measured value: C, 58.17, H, 5.16, N, 3.97.
6-(3-chlorphenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno [3,2-d] [1,3] oxazine-2-ketone
(0.12g adds KO in anhydrous THF (5.0ml) solution 0.34mmol) at [5-(3-chloro-phenyl)-2-(1-hydroxyl-1-methyl-ethyl)-thiene-3-yl-]-allyl carbamate
t(0.076g 0.068mmol), stirred 15 minutes Bu, used H
2The O cancellation adds minute quantity MeOH crystallization then in solution.Collect white crystal, mp 123-125 ℃ with B ü chner funnel.
1H NMR (DMSO-d
6) δ 1.64 (s, 6H), 7.05 (s, 1H), 7.37-7.48 (m, 2H), 7.53-7.56 (s, 1H), 7.67-7.68 (m, 1H), 10.41 (s, 1H); MS (EI) m/z 293/295 (M+H); C
17H
18ClNO
3S assay value: C, 57.24, H, 4.12, N, 4.77.Measured value: C, 56.93, H, 3.92, N, 4.97.
Embodiment 3 pharmacologys
As follows, the activity of usefulness PRE-luciferase experimental evaluation progestogen of the present invention in the CV-1 cell.Their scope of validity is 0.01nM-10 in vitro tests, 000nM.Arrive 30mg/kg for 1mg/kg in the in vivo test.
The purpose of this test is based on chemical compound influence to PRE-luciferase reporter activity in the CV-1 cell of personnel selection PR and PRE-luciferase plasmids cotransfection, determines the progestogenic or the anti-pregnant effect of chemical compound.Material used in this test is as follows:
A. culture medium: growth medium is as follows: contain 10% (v/v) hyclone (hot deactivation), 0.1mM MEM non essential amino acid, 100U/ml penicillin, 100mg/ml streptomycin and 2mM GlutaMax (GIBCO, DMEM BRL) (BioWhittaker).Test medium is as follows: contain the hyclone (heat inactivation) of 10% (v/v) activated carbon desorbing, MEM, 100U/ml penicillin, 100mg/ml streptomycin and the 2mM GlutaMax of 0.1mM MEM non essential amino acid (GIBCO, no phenol red DMEM (BioWhittaker) BRL).
B. the cultivation of cell, transfection, processing and luciferase test
The CV-1 cell stock solution is maintained in the growth medium.With 1.2 * 10
7The calf thymus DNA that individual cell, 5mgpLEM plasmid (inserting hPR-B at Sph1 and BamH1 site), 10mgpGL3 plasmid (two PRE are arranged in the luciferase sequence upstream) and 50mg supersound process are crossed carries out cotransfection as carrier DNA (250ml).
In 260V and 1,000mF carries out electroporation with Biorad Gene Pulser II.Behind the electroporation, cell is resuspended to growth medium, and on 96 orifice plates, inoculates with 40,000 cells/well (200 μ l).After the overnight incubation, change culture medium into test medium.In test medium, handle these cells then with contrast or test compounds.When the 3nM Progesterone, measure the contraception activity of chemical compound.Handle after 24 hours, discard culture medium, (GIBCO BRL) washs these cells 3 times with D-PBS.Each hole adds 50 μ l cell lysis buffer solution, and (WI), dull and stereotyped (Lab LineInstrument Inc) goes up vibration 15 minutes at the titration oscillator plate for Promega, Madison.Measure the activity of luciferase with the luciferase reagent of Promega.
C. interpretation of result
Various processing repeat 4 times at least.Be matched with the variance and the non-linear dose response curve of agonist and antagonist pattern with the data analysis of logarithm conversion.Reduce the influence of outlier (outlier) with the Huber weighting method.With the numerical computations EC that converts again
50Or IC
50In two one-way analysises of variance and non-linear response analysis, and use JMP software (SAS Institute, Inc.).
D. control compound
Progesterone and trimegestone be progestogen in contrast, and RU486 is gestation in contrast.All control compounds are all tested in full dose response curve, and calculate EC
50Or IC
50Value.
The expectation EC of contrast progestogen in three independent studies of table 1.
50, standard deviation (SE) and 95% confidence interval (CI)
EC
5095%CI chemical compound experiment (nM) SE lower limit upper limit Progesterone 1 0.616 0.026 0.509 0.746
2 0.402 0.019 0.323 0.501
3 0.486 0.028 0.371 0.637Trimegeston 1 0.0075 0.0002?0.0066?0.0085
e
2 0.0081 0.0003?0.0070?0.0094
3 0.0067 0.0003?0.0055?0.0082
The expectation IC of gestation RU486 in three independent studies of table 2.
50, standard deviation (SE) and 95% confidence interval (CI)
IC50 95%CI chemical compound experiment (nM) SE lower limit upper limit RU486 1 0.028 0.002 0.019 0.042
2 0.037 0.002 0.029 0.048
3 0.019 0.001 0.013 0.027
Progestogenic activity: compare with control vector, the chemical compound that makes the PRE-uciferase activity significantly increase (p＜0.05) is thought activated.
Anti-pregnant activity: the chemical compound that significantly reduces the activity (p＜0.05) of the inductive PRE-luciferase of 3nM Progesterone.
EC
50: can increase PRE-uciferase activity maximum one half, compound concentrations (be defaulted as " nM ') and standard deviation.
IC
50: can reduce the inductive PRE-uciferase activity of 3nM Progesterone maximum one half, compound concentrations (being defaulted as " nM ") and standard deviation.
This paper includes the publication of all references as a reference in.Though the present invention is described with preferred embodiment, be appreciated that not breaking away from spirit of the present invention can also do some improvement.These improvement are in the appended claim scope of the present invention 9.
Claims (19)
1. a method of contraception is characterized in that, described method comprises and gave the women of child-bearing age continuous 28 days:
A) phase I gives the progestogenic medicine of a 14-24 daily dose unit, and the progestogenic activity of progestogenic medicine is equivalent to 35-100 microgram levonorgestrel;
B) second stage, the formula 1 that gives a 1-11 daily dose unit resists pregnant chemical compound or its pharmaceutically acceptable salt, and daily dose unit is the 2-50 milligram:
It is characterized in that, wherein:
A and B respectively are the substituent groups that is selected from S, CH or N;
Condition is when A is S, and B is CH or N; Condition is
When B was S, A was CH or N;
With A and B can not be CH simultaneously;
With when A and B are N, a N can be randomly by C
1-C
6Alkyl replaces;
R
1And R
2Respectively be to be selected from following substituent group: H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
2-C
6The C of alkenyl, replacement
2-C
6Alkenyl, C
2-C
6The C of alkynyl, replacement
2-C
6Alkynyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
AOr NR
BCOR
A
Or R
1And R
2Condense formation:
A) the optional 3-8 unit spirocyclane basic ring that replaces; Or
B) the optional 3-8 unit volution alkene basic ring that replaces; Or
C) the optional 3-8 unit volution that replaces contains 1-3 hetero atom that is selected from O, S and N;
R
ABe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
BBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
6The C of alkenyl, replacement
1-C
6Alkenyl, alkynyl or the alkynyl, the COR that replace
C
R
CBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
4Be the trisubstituted benzene ring that contains substituent X, Y and Z as follows:
X is selected from halogen, CN, C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3The C of alkylthio group, replacement
1-C
3Alkylthio group, C
1-C
3The C of aminoalkyl, replacement
1-C
3Aminoalkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 or 6 yuan of heterocycles, COR
D, OCOR
D, or NR
ECOR
D
R
DBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
EBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
Y and Z are selected from following substituent group: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
3Alkyl or C
1-C
3Alkylthio group;
Or
R
4Be 5 or 6 yuan of rings, contain 1,2 or 3 and be selected from following hetero atom O, S, SO, SO
2Or NR
5, and these 5 or 6 yuan of rings are randomly contained 1-2 and respectively are selected from following substituent group and replace: H, halogen, CN, NO
2, and C
1-C
3Alkyl, C
1-C
3Alkoxyl, C
1-C
3Aminoalkyl, COR
F, or NR
GCOR
F
R
FBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
GBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
5Be H or C
1-C
3Alkyl;
W is O or chemical bond;
C) optional, be used for acceptable oral placebo on the materia medicas of phase III of residue day of 28 Consecutive Days, daily dose unit's sum of first, second and phase III equals 28, does not wherein give gestation, progestogen or estrogen.
2. the method for claim 1 is characterized in that, described progestogenic medicine is a levonorgestrel, and gestation is chemical compound or its pharmaceutically acceptable salt with formula I as claimed in claim 1, wherein:
A and B respectively are the substituent groups that is selected from S, CH or N;
Condition is when A is S, and B is CH or N;
With when B is S, A is CH or N;
With A and B can not be CH simultaneously;
With when A and B are N, a N can be randomly by C
1-C
6Alkyl replaces;
R
1Be H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
A, or NR
BCOR
A
R
2Be H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
2-C
6The C of alkenyl, replacement
2-C
6Alkenyl, C
2-C
6The C of alkynyl, replacement
2-C
6Alkynyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
A, or NR
BCOR
A
Or R
1And R
2Condense formation:
A) the optional 3-8 unit spirocyclane basic ring that replaces; Or
B) the optional 3-8 unit volution alkene basic ring that replaces; Or
C) the optional 3-8 unit volution that replaces contains 1-3 hetero atom that is selected from O, S and N;
R
ABe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
BBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
6The C of alkenyl, replacement
1-C
6Alkenyl, alkynyl or the alkynyl, the COR that replace
C
R
CBe H, C
1-C
4The C of alkyl, replacement
1-C
4The aryl of alkyl, aryl, replacement, C
1-C
4The C of alkoxyl, replacement
1-C
4Alkoxyl, C
1-C
4Aminoalkyl or the C that replaces
1-C
4Aminoalkyl;
R
4Be the trisubstituted benzene ring that contains substituent X, Y and Z as follows:
X is selected from halogen, CN, C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3The C of alkylthio group, replacement
1-C
3Alkylthio group, C
1-C
3The C of aminoalkyl, replacement
1-C
3Aminoalkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 yuan of heterocycles, COR
D, OCOR
D, or NR
ECOR
D
R
DBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
EBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
Y and Z are selected from following substituent group: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
3Alkyl or C
1-C
3Alkylthio group;
Or
R
4Be 5 or 6 yuan of rings, contain 1,2 or 3 and be selected from following hetero atom O, S, SO, SO
2Or NR
5, and these 5 or 6 yuan of rings randomly respectively are selected from following substituent group replacement by 1-2: H, halogen, CN, NO
2, amino and C
1-C
3Alkyl, C
1-C
3Alkoxyl;
R
5Be H or C
1-C
3Alkyl;
W is O or chemical bond.
3. the method for claim 1 is characterized in that, described progestogenic medicine is a levonorgestrel, and gestation is chemical compound or its pharmaceutically acceptable salt with formula I as claimed in claim 1, wherein:
A and B respectively are the substituent groups that is selected from S, CH or N;
Condition is when A is S, and B is CH or N;
With when B is S, A is CH or N;
With A and B can not be CH simultaneously;
R
1=R
2And be selected from: C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, or R
1And R
2Condense the spiro cycloalkyl group that the 3-6 unit volution of formation is constituted;
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl or COR
C
R
CBe H, C
1-C
4Alkyl or C
1-C
4Alkoxyl;
R
4Be the disubstituted benzenes ring that contains substituent X and Y as follows:
X is selected from following group, comprising: halogen, CN, C
1-C
3Alkoxyl, C
1-C
3Alkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 yuan of heterocycles or C
1-C
3Alkylthio group;
Y is in the following substituent group of 4 ' or 5 ' be selected from, and comprising: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
4Alkyl, C
1-C
3Alkylthio group;
Or
R
4Be 5 yuan of rings of following structure
U is O, S or NR
5,
R
5Be H or C
1-C
3Alkyl or C
1-C
4CO
2Alkyl;
X ' is selected from following group: halogen, CN, NO
2, C
1-C
3Alkyl or C
1-C
3Alkoxyl;
Y ' is: H or C
1-C
4Alkyl;
Or
R
4Be 6 yuan of rings of following structure:
X
1Be N or CX
2
X
2Be halogen, CN or NO
2
W is O or chemical bond.
4. the method for claim 1 is characterized in that, described progestogenic medicine is a levonorgestrel, and gestation is chemical compound or its pharmaceutically acceptable salt of formula I as claimed in claim 1, wherein:
R
1=R
2And be selected from: C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, or by R
1And R
2Condense and form the spiro cycloalkyl group that 3-6 unit volution is constituted;
And A, B, R
3, R
C, R
4, X, Y, U, R
5, X ', Y ', X
1, X
2, R
6, R
7, R
8, R
9With W such as claim 3 definition.
5. the method for claim 1 is characterized in that, described progestogenic medicine is a levonorgestrel, and gestation is chemical compound or its pharmaceutically acceptable salt of formula I as claimed in claim 1, wherein:
R
1And R
2Condense and form 3-6 unit volution;
And A, B, R
3, R
C, R
4, X, Y, U, R
5, X ', Y ', X
1, X
2, R
6, R
7, R
8, R
9With W such as claim 3 definition.
6. a method of contraception is characterized in that, described method comprises and gave the women of child-bearing age continuous 28 days:
A) phase I gives the progestogenic medicine of a 14-24 daily dose unit, and the progestogenic activity of progestogenic medicine is equivalent to 35-100 microgram levonorgestrel;
B) second stage gives anti-pregnant chemical compound or its pharmaceutically acceptable salt of the following formula of a 1-11 daily dose unit, and daily dose unit is the 2-50 milligram:
R
1And R
2Respectively be to be selected from following substituent group: H, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
2-C
6The C of alkenyl, replacement
2-C
6Alkenyl, C
2-C
6The C of alkynyl, replacement
2-C
6Alkynyl, C
3-C
8The C of cycloalkyl, replacement
3-C
8The heterocycle of the aryl of cycloalkyl, aryl, replacement, heterocycle, replacement, COR
AOr NR
BCOR
A
Or R
1And R
2Condense formation:
A) 3-6 unit spirocyclane basic ring; Or
B) 3-6 unit volution alkene basic ring; Or
R
3Be H, OH, NH
2, C
1-C
6The C of alkyl, replacement
1-C
6Alkyl, C
3-C
6The C of alkenyl, replacement
1-C
6Alkenyl, alkynyl or the alkynyl, the COR that replace
C
R
BBe H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
R
CBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
R
4Be the trisubstituted benzene ring that contains substituent X, Y and Z as follows:
X is selected from halogen, CN, C
1-C
3The C of alkyl, replacement
1-C
3Alkyl, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3The C of alkylthio group, replacement
1-C
3Alkylthio group, C
1-C
3The C of aminoalkyl, replacement
1-C
3Aminoalkyl, NO
2, C
1-C
3Perfluoroalkyl, contain 1-3 heteroatomic 5 or 6 yuan of heterocycles, COR
D, OCOR
D, or NR
ECOR
D
R
DBe H, C
1-C
3The C of alkyl, replacement
1-C
3The aryl of alkyl, aryl, replacement, C
1-C
3The C of alkoxyl, replacement
1-C
3Alkoxyl, C
1-C
3Aminoalkyl or the C that replaces
1-C
3Aminoalkyl;
RE is H, C
1-C
3Alkyl or the C that replaces
1-C
3Alkyl;
Y and Z are selected from following substituent group: H, halogen, CN, NO
2, C
1-C
3Alkoxyl, C
1-C
3Alkyl or C
1-C
3Alkylthio group;
C) optional, be used for acceptable oral placebo on the materia medicas of phase III of residue day of 28 Consecutive Days, daily dose unit's sum of first, second and phase III equals 28, does not wherein give gestation, progestogen or estrogen.
7. the method for claim 1 is characterized in that, described gestation chemical compound is 6-(3-chlorphenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno [2,3-d] [1,3]-oxazines-2-ketone, or its pharmaceutically acceptable salt.
8. the method for claim 1; it is characterized in that described progestogenic medicine is selected from: levonorgestrel, norgestrel, desogestrel, 3-ketone desogestrel, norethindrone, gestodene, SH 420, norgestimate, husky progesterone difficult to understand, acetic acid cyproterone, trimegestone, dienogest, spirorenone, nomegestrol or (17-deacetylation) norgestimate in the wrong.
9. the method for claim 1 is characterized in that, described method comprises and followingly gives continuous 28 day cycle to the women of child-bearing age:
A) be used for the progestogenic medicine of 21 daily dose units of phase I, the progestogenic activity of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel;
B) be used for the described gestation chemical compound of claim 1 of 3 daily dose units of second stage, the gestation chemical compound that daily dose is the 2-50 milligram is contained in each daily dose unit; With
C) can randomly give acceptable oral placebo on the materia medica of 4 daily dose units, each in 28 diurnal periodicitys after first and second stages day gives.
10. a contraceptive device is characterized in that, this method is included in and gives the women at reproduction age following material in successive 28 days:
A) phase I gives the progestogenic medicine and the ethinylestradiol of a 18-21 daily dose unit, and the progestogenic activity of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel, and the daily dose scope of ethinylestradiol is the 10-35 microgram; With
B) second stage gives the described gestation of claim 1 of a 1-7 daily dose unit, and its daily dose is the 2-50 milligram; With
C) optionally in continuous 28 days, remaining each day give acceptable oral placebo on the materia medica.
11. method as claimed in claim 10 is characterized in that, described method is included in and gives the women of child-bearing age following material in the continuous 28 days time:
A) phase I gives the progestogenic medicine and the ethinylestradiol of 21 daily dose units, and the progestogenic activity of progestogenic medicine is equivalent to 35-100 microgram levonorgestrel, and ethinylestradiol daily dose scope is the 10-35 microgram; With
B) second stage gives the described gestation of claim 1 of 3 daily dose units, and its daily dose is the 2-50 milligram; With
C) the optional phase III, give acceptable oral placebo on the materia medica of 4 daily dose units.
12. a contraceptive device is characterized in that, described method is included in during continuous 28 days and gives the women of child-bearing age following material:
A) phase I gives the progestogenic medicine and the ethinylestradiol of a 18-21 daily dose unit, and the daily dose of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel on progestogenic activity, and ethinylestradiol daily dose scope is the 10-35 microgram; With
B) second stage gives 1-7 a daily dose unit, and it is that the described gestation of claim 1 and the concentration of 2-50 milligram is the ethinylestradiol of 10-35 microgram that concentration is contained in each daily dose unit; With
C) the optional phase III gives acceptable oral placebo on the materia medica of daily dose unit, and daily dose unit adds up to 28.
13. method as claimed in claim 12 is characterized in that, described method is included in during continuous 28 days and gives the women of child-bearing age following material:
A) phase I gives 21 daily dose units, and progestogenic medicine and ethinylestradiol are contained in each daily dose unit, and the daily dose of progestogenic medicine is equivalent to 35-100 microgram levonorgestrel on progestogenic activity, and the daily dose scope of ethinylestradiol is the 10-35 microgram; With
B) second stage gives 3 daily dose units, and it is the ethinylestradiol of 10-35 microgram that described gestation of claim 1 and the concentration that concentration is the 2-50 milligram is contained in each daily dose unit; With
C) the optional phase III, give acceptable oral placebo on the materia medica of 4 daily dose units.
14. a pharmaceutically available medicine box that is adapted to oral administration is characterized in that described medicine comprises:
A) be used for the progestogenic medicine of the 14-21 daily dose unit of phase I, the progestogenic activity of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel;
B) be used for the described gestation chemical compound of claim 1 of a 1-11 daily dose unit of second stage, the gestation chemical compound that daily dose is the 2-50 milligram is contained in each daily dose unit; With
C) be used for acceptable oral placebo daily dose unit on the materia medica of phase III;
Wherein phase I, second stage and the daily dose unit of phase III sum equal 28.
15. the pharmaceutically available medicine box that is adapted to oral administration as claimed in claim 14 is characterized in that described medicine box comprises:
A) be used for the progestogenic medicine of 21 daily dose units of phase I, the progestogenic activity of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel;
B) be used for the described gestation chemical compound of claim 1 of 3 daily dose units of second stage, the gestation chemical compound that daily dose is the 2-50 milligram is contained in each daily dose unit; With
C) be used for acceptable oral placebo on the materia medica of 4 daily dose units of phase III.
16. a pharmaceutically available medicine box that is applicable to oral administration every day is characterized in that described medicine box comprises:
A) be used for the progestogenic medicine and the ethinylestradiol of the 18-21 daily dose unit of phase I, the progestogenic activity of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel, and the daily dose scope of ethinylestradiol is the 10-35 microgram; With
B) be used for the described gestation chemical compound of claim 1 of a 1-7 daily dose unit of second stage, its daily dose is the 2-50 milligram; With
C) be used for acceptable oral placebo on the materia medica of a 0-9 daily dose unit of phase III;
Wherein phase I, second stage and the sum of the daily dose unit in the phase III equal 28.
17. the pharmaceutically available medicine box that is applicable to oral administration every day as claimed in claim 16 is characterized in that described medicine box comprises:
A) be used for the progestogenic medicine and the ethinylestradiol of 21 daily dose units of phase I, the progestogenic activity of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel, and the daily dose scope of ethinylestradiol is the 10-35 microgram; With
B) be used for the described gestation of claim 1 of 3 daily dose units of second stage, its daily dose is the 2-50 milligram; With
C) be used for acceptable oral placebo on the materia medica of 4 daily dose units of phase III.
18. a pharmaceutically available medicine box that is applicable to oral administration every day is characterized in that described medicine box comprises:
A) be used for the 18-21 daily dose unit of phase I, progestogenic medicine and ethinylestradiol are contained in each daily dose unit, and the daily dose of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel on progestogenic activity, and the daily dose scope of ethinylestradiol is the 10-35 microgram;
B) be used for the 1-7 daily dose unit of second stage, it is that the described gestation of claim 1 and the concentration of 2-50 milligram is the ethinylestradiol of 10-35 microgram that concentration is contained in each daily dose unit; With
C) be used for acceptable oral placebo on the materia medica of a 0-9 daily dose unit of phase III;
Wherein phase I, second stage and the sum of the daily dose unit in the phase III equal 28.
19. the pharmaceutically available medicine box that is applicable to oral administration every day as claimed in claim 18 is characterized in that described medicine box comprises:
A) be used for 21 daily dose units of phase I, progestogenic medicine and ethinylestradiol are contained in each daily dose unit, and the daily dose of progestogenic medicine is equivalent to 35-150 microgram levonorgestrel on progestogenic activity, and the daily dose scope of ethinylestradiol is the 10-35 microgram;
B) be used for 3 daily dose units of second stage, it is the ethinylestradiol of 10-35 microgram that described gestation of claim 1 and the concentration that concentration is the 2-50 milligram is contained in each daily dose unit; With
C) be used for acceptable oral placebo on the materia medica of 4 daily dose units of phase III.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30500799A | 1999-05-04 | 1999-05-04 | |
| US09/305,007 | 1999-05-04 | ||
| US09/552,545 US6380178B1 (en) | 1999-05-04 | 2000-04-19 | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
| US09/552,545 | 2000-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1349422A true CN1349422A (en) | 2002-05-15 |
Family
ID=26974352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00807137 Pending CN1349422A (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbramates and amide derivatives |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1349422A (en) |
| AU (1) | AU5125100A (en) |
-
2000
- 2000-05-01 AU AU51251/00A patent/AU5125100A/en not_active Abandoned
- 2000-05-01 CN CN 00807137 patent/CN1349422A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU5125100A (en) | 2000-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1292746C (en) | Amino-sulfonyl-containing active compound (COX-2 inhibitors), polyethylene glycol and removing free radical antioxidate and liquid | |
| CN1107505C (en) | Synergistic combination of AIDS antiviral compounds and HIV inhibitor | |
| CN1662241A (en) | Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions | |
| CN1349413A (en) | Contraceptive compositions containing quinazolinone and benzoxazine derivatives | |
| CN1662234A (en) | Use of thio-oxindole derivatives in treatment of hormone-related conditions | |
| CN101052641A (en) | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | |
| US6306851B1 (en) | Cyclocarbamate and cyclic amide derivatives | |
| CN1349531A (en) | Cyanopyrroles as progesterone receptor agonists | |
| CN1403157A (en) | Method for treating female sexual dysfunction and evaluating compound for treating female sexual dysfunction | |
| CN1681495A (en) | Combination therapy for hyperplasia diseases | |
| CN1922189A (en) | Spirocyclic cyclohexane derivatives with affinity for the ORL1-receptor | |
| KR20070039567A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
| US20080045560A1 (en) | Pyrrolidine and related derivatives useful as PR modulators | |
| CN1349537A (en) | Cyclic urea and cyclic amide derivatives | |
| CN1455769A (en) | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | |
| TW201900171A (en) | Use of an EZH2 inhibitor in combination with a BTK inhibitor for the preparation of a medicament for treating tumor | |
| CN1349412A (en) | Contraceptive compositions containing cyclic urea and amide derivatives | |
| US6380178B1 (en) | Cyclic regimens using cyclocarbamate and cyclic amide derivatives | |
| CN1201820C (en) | Compositions containing benzimidazolones and progestogens | |
| JP5137578B2 (en) | Trisubstituted thiophenes as progesterone receptor modulators | |
| CN1179753C (en) | Contraceptive compositions contaiing antiprogesting and progestinic | |
| CN1138770C (en) | 6-carbonyl-3-(4-[2-(pierid-1-yl)elhoyl]phenoxy)-2(4-methoxylphenyl) benzo[b]thiophene salt crystal | |
| CN1349422A (en) | Contraceptive compositions containing cyclic carbramates and amide derivatives | |
| CN1349538A (en) | Cyclocarbamate and cyclic amide derivatives | |
| CN1349416A (en) | Contraceptive compositions contaiing indoline derivatives and progestational agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |